Summary of findings 1: Efficacy and safety of IVT lampalizumab 4‐weekly (monthly) vs sham
Change in LLVA from baseline at 1 year (ETDRS letters) · adults with GA due to AMD
1 finding from 1 review
- no estimate extracted2 studies · 1068 participantsHigh